サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1730932

肝硬変の世界市場レポート 2025年

Liver Cirrhosis Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.37円
肝硬変の世界市場レポート 2025年
出版日: 2025年05月16日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肝硬変の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR8.0％で27億4,000万米ドルに成長します。予測期間中の成長は、肝炎感染の増加、経済成長の上昇、都市化の進展、ライフスタイルの変化、医療ツーリズムの成長に起因しています。この期間の主要動向には、診断ツールの進歩、技術革新、協力・提携、人工知能の統合、ホリスティック療法の導入などがあります。

アルコール消費量の増加が肝硬変市場の成長を牽引すると予想されます。アルコールの消費量は、一般的にその量と頻度によって測定されるが、日々のストレスから人々をリラックスさせ、集まりでの社会的つながりを促進し、くつろぎのひとときを充実させることから増加しています。さらに、アルコールはメディアを通じて広く宣伝され、様々な場面でより身近なものとなっています。過度のアルコール摂取がある患者に対して、肝硬変の治療は、主に禁酒、薬剤療法、支持療法による肝障害の管理に重点を置き、カウンセリングやリハビリテーションを通じてアルコール依存症に対処します。例えば、2023年3月、アイルランドを拠点とするデータ収集機関であるNational Drugs Libraryによると、2022年の15歳以上のアルコール消費量は1人当たり平均10.2リットルとなり、2021年から7.6％増加しました。このアルコール消費量の増加が肝硬変市場の成長に寄与しています。

肝硬変市場の企業は、患者の予後を改善し治療の選択肢を広げるため、能動型埋め込み医療機器の開発など、新たな治療の進歩に注力しています。能動植込み型医療機器とは、体内の臓器機能をモニター、サポート、改善するために設計された電子的に駆動するインプラントのことです。例えば、2024年12月、ベルギーを拠点とする医療機器会社Sequana Medical NVは、肝硬変に起因する再発性または難治性の腹水を管理するために米国で承認された初の能動植込み型医療機器であるalfapumpシステムの米国FDA承認を取得しました。この画期的な技術は、過剰な腹水を膀胱に移送することにより、体液管理のための継続的で自動化されたソリューションを提供し、侵襲的な腹腔穿刺の必要性を大幅に低減します。アルファポンプシステムは、患者の転帰と生活の質を改善する上で重要な前進であり、米国における対応可能な市場は約7万人です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の肝硬変PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の肝硬変市場：成長率分析
  • 世界の肝硬変市場の実績：規模と成長、2019～2024年
  • 世界の肝硬変市場の予測：規模と成長、2024～2029年、2034年
  • 世界の肝硬変総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の肝硬変市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • アルコール性肝硬変
  • 萎縮性肝硬変
  • 胆汁性肝硬変
  • 心臓性肝硬変
  • 原因不明の肝硬変
  • 世界の肝硬変市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
  • 抗生物質
  • 免疫抑制剤
  • その他
  • 世界の肝硬変市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院
  • 専門クリニック
  • 外来手術センター
  • 学術研究機関
  • その他
  • 世界の肝硬変市場、アルコール性肝硬変のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 代償性アルコール性肝硬変
  • 非代償性アルコール性肝硬変
  • アルコール性脂肪肝炎（ASH）関連肝硬変
  • 世界の肝硬変市場、萎縮性肝硬変のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 壊死後萎縮性肝硬変
  • 大結節性萎縮性肝硬変
  • 小結節性萎縮性肝硬変
  • 世界の肝硬変市場、胆汁性肝硬変のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 原発性胆汁性肝硬変（PBC）
  • 二次性胆汁性肝硬変
  • 自己免疫性胆汁性肝硬変
  • 世界の肝硬変市場、心臓性肝硬変のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 右心不全誘発性肝硬変
  • 慢性受動性うっ血性肝硬変
  • 虚血性肝炎肝硬変
  • 世界の肝硬変市場、原因不明の肝硬変のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 非アルコール性脂肪肝炎（NASH）関連肝硬変
  • 特発性肝硬変
  • メタボリックシンドローム関連肝硬変

第7章 地域別・国別分析

  • 世界の肝硬変市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の肝硬変市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 肝硬変市場：競合情勢
  • 肝硬変市場：企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche AG
    • Merck & Co. Inc.
    • AbbVie Inc.
    • Bayer AG

第31章 その他の大手企業と革新的企業

  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Abbott Laboratories
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Novo Nordisk A/S
  • Viatris Inc.
  • Grifols Therapeutics LLC
  • Shionogi Inc.
  • Galectin Therapeutics Inc.
  • NGM Biopharmaceuticals Inc.
  • Madrigal Pharmaceuticals Inc.
  • Akero Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

  • 肝硬変市場、2029年：新たな機会を提供する国
  • 肝硬変市場、2029年：新たな機会を提供するセグメント
  • 肝硬変市場、2029年：成長戦略
    • 市場動向による戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34604

Liver cirrhosis is a progressive condition where healthy liver tissue is gradually replaced by scar tissue, impairing the liver's ability to function effectively. This disease results from prolonged liver damage caused by factors such as chronic alcohol consumption, viral hepatitis, or fatty liver disease.

The main types of liver cirrhosis include alcoholic cirrhosis, atrophic cirrhosis, biliary cirrhosis, cardiac cirrhosis, and cryptogenic cirrhosis. Alcoholic cirrhosis is a severe form of liver disease caused by long-term excessive alcohol consumption, which leads to liver scarring, dysfunction, and potential liver failure. Various treatment options are available, including antibiotics, immunosuppressants, and other therapies. Key end users of these treatments include hospitals, specialty clinics, ambulatory surgical centers, academic and research institutes, among others.

The liver cirrhosis market research report is one of a series of new reports from The Business Research Company that provides liver cirrhosis market statistics, including the liver cirrhosis industry global market size, regional shares, competitors with the liver cirrhosis market share, detailed liver cirrhosis market segments, market trends, and opportunities, and any further data you may need to thrive in the liver cirrhosis industry. This liver cirrhosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The liver cirrhosis market size has grown rapidly in recent years. It will grow from $1.86 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period can be attributed to the rising prevalence of liver diseases, high alcohol consumption, an aging population, higher healthcare expenditure, and growing government initiatives.

The liver cirrhosis market size is expected to see rapid growth in the next few years. It will grow to $2.74 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth during the forecast period can be attributed to the increasing incidence of hepatitis infections, rising economic growth, greater urbanization, lifestyle changes, and the growth of medical tourism. Key trends during this period include advancements in diagnostic tools, technological innovations, collaborations and partnerships, the integration of artificial intelligence, and the incorporation of holistic therapies.

The rising consumption of alcohol is expected to drive the growth of the liver cirrhosis market. Alcohol consumption, typically measured by its quantity and frequency, is increasing as it helps people relax from daily stress, promotes social connections at gatherings, and enhances moments of relaxation. Additionally, alcohol is widely advertised through media and is more accessible in various settings. For patients with excessive alcohol consumption, liver cirrhosis treatment primarily focuses on managing liver damage through abstinence, medications, and supportive care, while addressing alcohol dependence through counseling and rehabilitation. For example, in March 2023, the National Drugs Library, an Ireland-based data collection organization, reported that in 2022, the average alcohol consumption among individuals aged 15 and older increased to 10.2 liters of pure alcohol per capita, reflecting a 7.6% rise from 2021. This increase in alcohol consumption is contributing to the growth of the liver cirrhosis market.

Companies in the liver cirrhosis market are focusing on new treatment advancements, such as the development of active implantable medical devices, to improve patient outcomes and expand treatment options. Active implantable medical devices are electronically powered implants designed to monitor, support, or improve organ function within the body. For example, in December 2024, Sequana Medical NV, a Belgium-based medical device company, received U.S. FDA approval for its alfapump system, the first active implantable medical device approved in the U.S. for managing recurrent or refractory ascites caused by liver cirrhosis. This breakthrough technology offers a continuous, automated solution for fluid management by transferring excess abdominal fluid to the bladder, significantly reducing the need for invasive paracentesis. The alfapump system represents a significant step forward in improving patient outcomes and quality of life, with an addressable market of around 70,000 patients in the U.S.

In September 2023, Galectin Therapeutics, a U.S.-based company specializing in liver cirrhosis treatment, partnered with HistoIndex to present their findings on liver cirrhosis at the 9th Paris NASH meeting. Through this collaboration, the two companies aim to utilize artificial intelligence to enhance the analysis of liver cirrhosis histology, providing deeper insights into disease progression and the effectiveness of treatments. HistoIndex is a Singapore-based company specializing in medical technology.

Major players in the liver cirrhosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Viatris Inc., Grifols Therapeutics LLC, Shionogi Inc., Galectin Therapeutics Inc., NGM Biopharmaceuticals Inc., Madrigal Pharmaceuticals Inc., Akero Therapeutics Inc.

North America was the largest region in the liver cirrhosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the liver cirrhosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liver cirrhosis market consists of revenues earned by entities providing services such as diagnosis and screening services, medical treatment, management services, and patient support. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cirrhosis market also includes sales of medications, diagnostic tools, medical devices, and therapeutic treatments. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liver Cirrhosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liver cirrhosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liver cirrhosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liver cirrhosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Alcoholic Cirrhosis; Atrophic Cirrhosis; Biliary Cirrhosis; Cardiac Cirrhosis; Cryptogenic Cirrhosis
  • 2) By Treatment: Antibiotics; Immunosuppressants; Other Treatments
  • 3) By End Users: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Academic And Research Institutes; Other End Users
  • Sub Segments:
  • 1) By Alcoholic Cirrhosis: Compensated Alcoholic Cirrhosis; Decompensated Alcoholic Cirrhosis; Alcoholic Steatohepatitis (ASH)-Associated Cirrhosis
  • 2) By Atrophic Cirrhosis: Post-necrotic Atrophic Cirrhosis; Macronodular Atrophic Cirrhosis; Micronodular Atrophic Cirrhosis
  • 3) By Biliary Cirrhosis: Primary Biliary Cirrhosis (PBC); Secondary Biliary Cirrhosis; Autoimmune Biliary Cirrhosis
  • 4) By Cardiac Cirrhosis: Right Heart Failure-Induced Cirrhosis; Chronic Passive Congestion Cirrhosis; Ischemic Hepatitis Cirrhosis
  • 5) By Cryptogenic Cirrhosis: Non-Alcoholic Steatohepatitis (NASH)-Associated Cirrhosis; Idiopathic Cirrhosis; Metabolic Syndrome-Associated Cirrhosis
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Liver Cirrhosis Market Characteristics

3. Liver Cirrhosis Market Trends And Strategies

4. Liver Cirrhosis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Liver Cirrhosis Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Liver Cirrhosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Liver Cirrhosis Market Growth Rate Analysis
  • 5.4. Global Liver Cirrhosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Liver Cirrhosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Liver Cirrhosis Total Addressable Market (TAM)

6. Liver Cirrhosis Market Segmentation

  • 6.1. Global Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alcoholic Cirrhosis
  • Atrophic Cirrhosis
  • Biliary Cirrhosis
  • Cardiac Cirrhosis
  • Cryptogenic Cirrhosis
  • 6.2. Global Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antibiotics
  • Immunosuppressants
  • Other Treatments
  • 6.3. Global Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Academic And Research Institutes
  • Other End Users
  • 6.4. Global Liver Cirrhosis Market, Sub-Segmentation Of Alcoholic Cirrhosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Compensated Alcoholic Cirrhosis
  • Decompensated Alcoholic Cirrhosis
  • Alcoholic Steatohepatitis (ASH)-Associated Cirrhosis
  • 6.5. Global Liver Cirrhosis Market, Sub-Segmentation Of Atrophic Cirrhosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Post-necrotic Atrophic Cirrhosis
  • Macronodular Atrophic Cirrhosis
  • Micronodular Atrophic Cirrhosis
  • 6.6. Global Liver Cirrhosis Market, Sub-Segmentation Of Biliary Cirrhosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Primary Biliary Cirrhosis (PBC)
  • Secondary Biliary Cirrhosis
  • Autoimmune Biliary Cirrhosis
  • 6.7. Global Liver Cirrhosis Market, Sub-Segmentation Of Cardiac Cirrhosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Right Heart Failure-Induced Cirrhosis
  • Chronic Passive Congestion Cirrhosis
  • Ischemic Hepatitis Cirrhosis
  • 6.8. Global Liver Cirrhosis Market, Sub-Segmentation Of Cryptogenic Cirrhosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Non-Alcoholic Steatohepatitis (NASH)-Associated Cirrhosis
  • Idiopathic Cirrhosis
  • Metabolic Syndrome-Associated Cirrhosis

7. Liver Cirrhosis Market Regional And Country Analysis

  • 7.1. Global Liver Cirrhosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Liver Cirrhosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Liver Cirrhosis Market

  • 8.1. Asia-Pacific Liver Cirrhosis Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Liver Cirrhosis Market

  • 9.1. China Liver Cirrhosis Market Overview
  • 9.2. China Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Liver Cirrhosis Market

  • 10.1. India Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Liver Cirrhosis Market

  • 11.1. Japan Liver Cirrhosis Market Overview
  • 11.2. Japan Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Liver Cirrhosis Market

  • 12.1. Australia Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Liver Cirrhosis Market

  • 13.1. Indonesia Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Liver Cirrhosis Market

  • 14.1. South Korea Liver Cirrhosis Market Overview
  • 14.2. South Korea Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Liver Cirrhosis Market

  • 15.1. Western Europe Liver Cirrhosis Market Overview
  • 15.2. Western Europe Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Liver Cirrhosis Market

  • 16.1. UK Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Liver Cirrhosis Market

  • 17.1. Germany Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Liver Cirrhosis Market

  • 18.1. France Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Liver Cirrhosis Market

  • 19.1. Italy Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Liver Cirrhosis Market

  • 20.1. Spain Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Liver Cirrhosis Market

  • 21.1. Eastern Europe Liver Cirrhosis Market Overview
  • 21.2. Eastern Europe Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Liver Cirrhosis Market

  • 22.1. Russia Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Liver Cirrhosis Market

  • 23.1. North America Liver Cirrhosis Market Overview
  • 23.2. North America Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Liver Cirrhosis Market

  • 24.1. USA Liver Cirrhosis Market Overview
  • 24.2. USA Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Liver Cirrhosis Market

  • 25.1. Canada Liver Cirrhosis Market Overview
  • 25.2. Canada Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Liver Cirrhosis Market

  • 26.1. South America Liver Cirrhosis Market Overview
  • 26.2. South America Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Liver Cirrhosis Market

  • 27.1. Brazil Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Liver Cirrhosis Market

  • 28.1. Middle East Liver Cirrhosis Market Overview
  • 28.2. Middle East Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Liver Cirrhosis Market

  • 29.1. Africa Liver Cirrhosis Market Overview
  • 29.2. Africa Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Liver Cirrhosis Market Competitive Landscape And Company Profiles

  • 30.1. Liver Cirrhosis Market Competitive Landscape
  • 30.2. Liver Cirrhosis Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Liver Cirrhosis Market Other Major And Innovative Companies

  • 31.1. Bristol-Myers Squibb Company
  • 31.2. AstraZeneca PLC
  • 31.3. Abbott Laboratories
  • 31.4. Novartis AG
  • 31.5. Takeda Pharmaceutical Company Limited
  • 31.6. Eli Lilly and Company
  • 31.7. Gilead Sciences Inc.
  • 31.8. Novo Nordisk A/S
  • 31.9. Viatris Inc.
  • 31.10. Grifols Therapeutics LLC
  • 31.11. Shionogi Inc.
  • 31.12. Galectin Therapeutics Inc.
  • 31.13. NGM Biopharmaceuticals Inc.
  • 31.14. Madrigal Pharmaceuticals Inc.
  • 31.15. Akero Therapeutics Inc.

32. Global Liver Cirrhosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liver Cirrhosis Market

34. Recent Developments In The Liver Cirrhosis Market

35. Liver Cirrhosis Market High Potential Countries, Segments and Strategies

  • 35.1 Liver Cirrhosis Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Liver Cirrhosis Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Liver Cirrhosis Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer